Free tool
FAERS Monitor: Perforomist
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022007 or its brand name (Perforomist, Formoterol Fumarate). Reports on generic versions are filed under their own applications.
Reports
4,757
Serious
3,925
83% of reports
Hospitalization
2,152
Death reported
538
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea1,333
- asthma1,150
- cough727
- wheezing608
- pneumonia530
- drug ineffective482
- therapeutic product effect incomplete461
- obstructive airways disorder430
- fatigue425
- headache405
- gastrooesophageal reflux disease393
- full blood count abnormal330
- hypertension322
- productive cough302
- sleep disorder due to a general medical condition263
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 29 |
| 2005 | 47 |
| 2006 | 66 |
| 2007 | 97 |
| 2008 | 66 |
| 2009 | 89 |
| 2010 | 106 |
| 2011 | 470 |
| 2012 | 457 |
| 2013 | 80 |
| 2014 | 69 |
| 2015 | 112 |
| 2016 | 141 |
| 2017 | 186 |
| 2018 | 222 |
| 2019 | 296 |
| 2020 | 359 |
| 2021 | 420 |
| 2022 | 372 |
| 2023 | 322 |
| 2024 | 288 |
| 2025 | 278 |
| 2026 | 185 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,402 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| obstructive airways disorderSignal | 430 | 177.8 | 162.1 | 72,541 |
| full blood count abnormalSignal | 330 | 142.3 | 128.0 | 44,756 |
| sleep disorder due to a general medical conditionSignal | 263 | 69.5 | 61.8 | 17,437 |
| wheezingSignal | 608 | 45.8 | 42.5 | 26,395 |
| asthmaSignal | 1,150 | 45.4 | 43.2 | 49,700 |
| therapeutic product effect incompleteSignal | 461 | 28.8 | 26.4 | 12,320 |
| productive coughSignal | 302 | 28.1 | 25.2 | 7,847 |
| gastrooesophageal reflux diseaseSignal | 393 | 21.7 | 19.7 | 7,726 |
| coughSignal | 727 | 11.5 | 10.7 | 7,027 |
| dyspnoeaSignal | 1,333 | 10.4 | 10.0 | 11,647 |
| pneumoniaSignal | 530 | 7.2 | 6.7 | 2,888 |
| hypertensionSignal | 322 | 6.7 | 6.1 | 1,579 |
| headacheSignal | 405 | 2.9 | 2.6 | 502 |
| fatigueSignal | 425 | 2.4 | 2.2 | 364 |
| drug ineffective | 482 | 1.6 | 1.5 | 120 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.